Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aflibercept in epithelial ovarian carcinoma.
Moroney JW, Sood AK, Coleman RL. Moroney JW, et al. Future Oncol. 2009 Jun;5(5):591-600. doi: 10.2217/fon.09.35. Future Oncol. 2009. PMID: 19519199 Free PMC article. Review.
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. Slomovitz BM, et al. Among authors: moroney jw. Gynecol Oncol. 2022 Mar;164(3):481-491. doi: 10.1016/j.ygyno.2021.12.031. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063278 Clinical Trial.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: moroney jw. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.
Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Moulder S, et al. J Clin Oncol. 2011 Jul 1;29(19):e572-5. doi: 10.1200/JCO.2010.34.0604. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482991 Clinical Trial. No abstract available.
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Moroney J, et al. Clin Cancer Res. 2012 Oct 15;18(20):5796-805. doi: 10.1158/1078-0432.CCR-12-1158. Epub 2012 Aug 27. Clin Cancer Res. 2012. PMID: 22927482 Clinical Trial.
31 results